Facon T.; Moreau P.; Martin T.G.; Spicka I.; Oriol A.; Koh Y.; Lim A.; Mikala G.; Rosinol L.; Yagci M.; Cavo M.; Yong K.; Risse M.-L.; Asset G.; Schwab S.; Martinez G., Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis, «HEMATOLOGICAL ONCOLOGY», 2022, 40, pp. 120 - 129 [articolo]Open Access
Richardson P.G.; Perrot A.; San-Miguel J.; Beksac M.; Spicka I.; Leleu X.; Schjesvold F.; Moreau P.; Dimopoulos M.A.; Huang J.S.-Y.; Minarik J.; Cavo M.; Prince H.M.; Malinge L.; Dubin F.; van de Velde H.; Anderson K.C., Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, «THE LANCET ONCOLOGY», 2022, 23, pp. 416 - 427 [articolo]
Mateos M.-V.; Weisel K.; De Stefano V.; Goldschmidt H.; Delforge M.; Mohty M.; Cavo M.; Vij R.; Lindsey-Hill J.; Dytfeld D.; Angelucci E.; Perrot A.; Benjamin R.; van de Donk N.W.C.J.; Ocio E.M.; Scheid C.; Gay F.; Roeloffzen W.; Rodriguez-Otero P.; Broijl A.; Potamianou A.; Sakabedoyan C.; Semerjian M.; Keim S.; Strulev V.; Schecter J.M.; Vogel M.; Wapenaar R.; Nesheiwat T.; San-Miguel J.; Sonneveld P.; Einsele H.; Moreau P., LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma, «LEUKEMIA», 2022, 36, pp. 1371 - 1376 [articolo]Open Access
Auteri G.; Bartoletti D.; Di Pietro C.; Sutto E.; Mazzoni C.; Romagnoli A.D.; Vianelli N.; Lazzarotto T.; Cavo M.; Palandri F., Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity, «LEUKEMIA RESEARCH», 2022, 116, Article number: 106819, pp. 0 - 0 [articolo]
Parisi, Sarah; Ruggeri, Loredana; Dan, Elisa; Rizzi, Simonetta; Sinigaglia, Barbara; Ocadlikova, Darina; Bontadini, Andrea; Giudice, Valeria; Urbani, Elena; Ciardelli, Sara; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Arpinati, Mario; Lewis, Russell E.; Bonifazi, Francesca; Marconi, Giovanni; Martinelli, Giovanni; Papayannidis, Cristina; Paolini, Stefania; Velardi, Andrea; Cavo, Michele; Lemoli, Roberto M.; Curti, Antonio, Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, «FRONTIERS IN IMMUNOLOGY», 2022, 12, pp. 1 - 6 [articolo]Open Access
Parisi S.; Ruggeri L.; Dan E.; Rizzi S.; Sinigaglia B.; Ocadlikova D.; Bontadini A.; Giudice V.; Urbani E.; Ciardelli S.; Sartor C.; Cristiano G.; Nanni J.; Zannoni L.; Chirumbolo G.; Arpinati M.; Lewis R.E.; Bonifazi F.; Marconi G.; Martinelli G.; Papayannidis C.; Paolini S.; Velardi A.; Cavo M.; Lemoli R.M.; Curti A., Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, «FRONTIERS IN IMMUNOLOGY», 2022, 12, Article number: 804988, pp. 1 - 6 [articolo]Open Access
Girmenia C.; Cavo M.; Corso A.; Di Raimondo F.; Musto P.; Offidani M.; Petrucci M.T.; Rosato A.; Barosi G., Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 172, Article number: 103623, pp. 0 - 0 [articolo]
Schjesvold F.H.; Dimopoulos M.-A.; Delimpasi S.; Robak P.; Coriu D.; Legiec W.; Pour L.; Spicka I.; Masszi T.; Doronin V.; Minarik J.; Salogub G.; Alekseeva Y.; Lazzaro A.; Maisnar V.; Mikala G.; Rosinol L.; Liberati A.M.; Symeonidis A.; Moody V.; Thuresson M.; Byrne C.; Harmenberg J.; Bakker N.A.; Hajek R.; Mateos M.-V.; Richardson P.G.; Sonneveld P.; Schjesvold F.; Nikolayeva A.; Tomczak W.; Pour L.; Spicka I.; Mikala G.; Rosinol L.; Konstantinova T.; Gatt M.; Illes A.; Abdulhaq H.; Dungarwalla M.; Grosicki S.; Hajek R.; Leleu X.; Myasnikov A.; Richardson P.G.; Avivi I.; Deeren D.; Gironella M.; Hernandez-Garcia M.T.; Martinez Lopez J.; Newinger-Porte M.; Ribas P.; Samoilova O.; Voog E.; Arnao-Herraiz M.; Carrillo-Cruz E.; Corradini P.; Dodlapati J.; Granell Gorrochategui M.; Huang S.-Y.; Jenner M.; Karlin L.; Kim J.S.; Kopacz A.; Medvedeva N.; Min C.-K.; Mina R.; Palk K.; Shin H.-J.; Sohn S.K.; Tache J.; Anagnostopoulos A.; Arguinano J.-M.; Cavo M.; Filicko J.; Garnes M.; Halka J.;, Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study, «THE LANCET. HAEMATOLOGY», 2022, 9, pp. 98 - 110 [articolo]
Manasanch E.E.; Beksac M.; Cavo M.; Knauf W.; Tsukada N.; Tekle C.; Zhao Z.; Martin T., MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. S405 - S406 [articolo]
Gozzetti A.; Guarnieri A.; Zamagni E.; Zakharova E.; Coriu D.; Bittrich M.; Pika T.; Tovar N.; Schutz N.; Ciofini S.; Pena C.; Rocchi S.; Rassner M.; Avivi I.; Waszczuk-Gajda A.; Chhabra S.; Usnarska-Zubkiewicz L.; Gonzalez-Calle V.; Mateos M.-V.; Bocchia M.; Bigi F.; Fullgraf H.; Bhasin-Chhabra B.; Gentile M.; Davila J.; Vesole D.H.; Cavo M.; Thapa B.; Crusoe E.; Einsele H.; Legiec W.; Charlinski G.; Jurczyszyn A., Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors, «AMERICAN JOURNAL OF HEMATOLOGY», 2022, 97, pp. 877 - 884 [articolo]Open Access
Monaldi C.; de Santis S.; Mancini M.; Papayannidis C.; Sartor C.; Rondoni M.; Bruno S.; Cavo M.; Soverini S., MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. S328 - S328 [articolo]
De Santis, S.; Monaldi, C.; Mancini, M.; Bruno, S.; Cavo, M.; Soverini, S., Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia, «ONCOTARGETS AND THERAPY», 2022, 15, pp. 103 - 116 [articolo]Open Access
Larocca A.; Leleu X.; Touzeau C.; Blade J.; Paner A.; Mateos M.-V.; Cavo M.; Maisel C.; Alegre A.; Oriol A.; Raptis A.; Rodriguez-Otero P.; Mazumder A.; Laubach J.; Nadeem O.; Sandberg A.; Orre M.; Torrang A.; Bakker N.A.; Richardson P.G., Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study, «BRITISH JOURNAL OF HAEMATOLOGY», 2022, 196, pp. 639 - 648 [articolo]
Palandri F.; Bartoletti D.; Iurlo A.; Bonifacio M.; Abruzzese E.; Caocci G.; Elli E.M.; Auteri G.; Tiribelli M.; Polverelli N.; Miglino M.; Heidel F.H.; Tieghi A.; Benevolo G.; Beggiato E.; Fava C.; Cavazzini F.; Pugliese N.; Binotto G.; Bosi C.; Martino B.; Crugnola M.; Ottaviani E.; Micucci G.; Trawinska M.M.; Cuneo A.; Bocchia M.; Krampera M.; Pane F.; Lemoli R.M.; Cilloni D.; Vianelli N.; Cavo M.; Palumbo G.A.; Breccia M., Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis, «CANCER», 2022, 128, pp. 2449 - 2454 [articolo]Open Access
Mancini M.; De Santis S.; Monaldi C.; Castagnetti F.; Lonetti A.; Bruno S.; Dan E.; Sinigaglia B.; Rosti G.; Cavo M.; Gugliotta G.; Soverini S., Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 901132, pp. 1 - 13 [articolo]Open Access
